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Abstract
Background: The interferon-γ (IFN-γ) ELISPOT assay is one of the most useful techniques for
immunological monitoring of cancer vaccine trials and has gained increased application as a measure
of specific T cell activation. However, it does not assess cell-mediated cytotoxicity directly as IFN-
γ secretion is not limited to only cytolytic cells. Granzyme B (GrB) is a key mediator of target cell
death via the granule-mediated pathway. Therefore, the release of GrB by cytolytic lymphocytes
upon effector-target interaction may be a more specific indicator of CTL and NK cytotoxic ability
than IFN-γ secretion.
Methods: We assessed whether the GrB ELISPOT assay is a viable alternative to the 51Cr-release
and IFN-γ ELISPOT assays for measuring antigen-specific CTL cytotoxicity. Direct comparisons
between the three assays were made using human CTL cell lines (αEN-EBV and αJY) and an in vitro
stimulated anti-Flu matrix peptide (FMP)-specific CTL.
Results: When the GrB ELISPOT was directly compared to the IFN-γ ELISPOT and 51Cr-release
assays, excellent cross-correlation between all three assays was shown. However, measurable IFN-
γ secretion in the ELISPOT assay was observed only after 1 hour of incubation and cytotoxicity
assessed via the 51Cr-release assay after 4 hours, whereas GrB secretion was detectable within 10
min of effector-target contact with significant secretion observed after 1 h. Titration studies
demonstrated a strong correlation between the number of effector cells and GrB spots per well.
Irrelevant targets or antigens did not induce significant GrB secretion. Additionally, GrB secretion
was abrogated when CTL cultures were depleted of CD8+ cells.
Conclusion: Our findings demonstrate that the GrB ELISPOT assay is a superior alternative to
the 51Cr-release assay since it is significantly more sensitive and provides an estimation of cytotoxic
effector cell frequency. Additionally, unlike the IFN-γ ELISPOT assay, the GrB ELISPOT directly
measures the release of a cytotolytic protein. Detection of low frequency tumor-specific CTL and
their specific effector functions can provide valuable insight with regards to immunological
responses.
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Background
The use of an interferon-γ (IFN-γ) ELISPOT assay has
gained increasing popularity as a surrogate measure of
cytotoxic T lymphocyte (CTL) activity. It has been deter-
mined to be one of the most useful assays to evaluate
immune response to cancer vaccines [1]. However, the
IFN-γ ELISPOT assay is not an exclusive measure of CTL
activity as non-cytotoxic cells can also secrete IFN-γ. Addi-
tionally, CTL with lytic activity do not always secrete IFN-
γ [2-6]. A more relevant approach to assess functional
activity of cytotoxic lymphocytes would be to measure the
secretion of molecules that are associated with lytic
activity.
One of the major mechanisms of cell-mediated cytotoxic-
ity involves exocytosis of cytoplasmic granules from the
effector toward the target cell. The granules contain a
number of proteins, including the pore-forming protein
perforin and a family of serine proteases called
granzymes, including Granzyme B (GrB). Granzyme B is
present mainly in the granules of CD8+ CTL and natural
killer (NK) cells [7-9] and may be involved in the lethal
hit that kills virus infected and tumorigenic cells [10-16].
Therefore, the release of Granzyme B in response to the
appropriate target may be used to evaluate cell-mediated
cytotoxicity by specific antitumor CTL generated by
vaccination.
The GrB ELISPOT assay was previously shown to measure
GrB release by GrB transfected CHO cells, T-cell lines and
PBMC from patients with AIDS [17]. In our study we
assessed whether the GrB ELISPOT assay could accurately
detect GrB secretion by CTL in different model systems
and how this assay correlates with the 51Cr-release assay.
We also compared the GrB ELISPOT assay with the IFN-γ
ELISPOT assay that is routinely used as a surrogate indica-
tor of CTL precursor frequency in immunological
monitoring.
Methods
Target cell lines
K562 (Human myelogenous leukemia cell line, ATCC,
Manassas, VA) were cultured in complete medium (CM)
consisting of RPMI 1640 (BioWhittaker, Walkersville,
MD) supplemented with 10% FBS (Hyclone, Logan, UT),
2 mM glutamine, 1 mM pyruvate, 100 U/ml Penicillin,
100 µg/ml Streptomycin (Gibco BRL Life Technologies,
Grand Island, NY). The C1R.A2 Human plasma leukemia
cell line which expresses a transfected genomic clone of
HLA-A2.1 was cultured in CM supplemented with 500 µg/
ml of G418 (Invitrogen, Carlsbad, CA). The JY (Human B
lymphoblastoid cell line) and EN-EBV (EBV transformed
autologous cells) cell lines served as targets for αJY and
αEBV CTL, respectively, and were grown in RPMI-1640
(BioWhittaker) containing 10% FBS (Hyclone), 2 mM L-
glutamine, 100 U/ml penicillin and 100 µg/ml streptomy-
cin (Gibco). All target cell lines were grown at 37°C, 5%
CO2. Prior to use in assays, C1R.A2 target cells were
pulsed with HLA-A2 binding peptides for 2 h at 37°C, 5%
CO2. Flu-Matrix peptide (FMP, NH2-G-I-L-G-F-V-F-T-L-
COOH, American Peptide Company, Inc., Sunnyvale,
CA) and melanoma common tumor antigen MART-1
(NH2-A-A-G-I-G-I-L-T-V-COOH, kindly provided by Dr.
Jay Berzofsky, NIH, Bethesda, MD) were utilized as rele-
vant and irrelevant HLA-A2 binding peptides,
respectively.
Preparation of human PBMC
Peripheral blood mononuclear cells (PBMC) were iso-
lated from venous blood of normal human volunteers by
buoyant density centrifugation over Ficoll-Paque (Phar-
macia, Piscataway, NJ). Aliquots of effector cells were cry-
opreserved in the vapor phase of liquid nitrogen for future
use in functional testing and flow cytometric analysis.
PBMC were cryopreserved in RPMI 1640 (BioWhittaker)
supplemented with 10% FBS (Hyclone), 2 mM L-
glutamine, 25 mM HEPES (Gibco) and 7.5% DMSO
(Fisher Chemical, Fair Lawn, NJ).
Generation of human anti-flu-matrix peptide (αFMP) CTL
PBMC from normal donors were screened for HLA-A2
expression by flow cytometry using direct staining with
anti-HLA-A2 FITC-conjugated monoclonal antibody
(One Lambda Inc., Canoga Park, CA). PBMC (3 × 106)
were resuspended in 2 ml of CM supplemented with 1000
U/ml of IL-7 (Peprotech, Rocky Hill, NJ) and seeded in 24
well plates (Costar, Corning, NY). FMP (American Peptide
Company, Inc.) was added to the PBMC at a final concen-
tration of 5 µg/ml. The CTL were grown at 37°C, 12%
CO2. At day 2 and day 5, 20 IU/ml of IL-2 (Hoffmann-
LaRoche) were added. Cells were assayed at day 7 of
culture.
Depletion of CD8+ cells from CTL cultures was performed
as previously described [18]. Briefly, 2 × 107 PBMC were
incubated for 40 min on ice with 100 µl anti-CD8 (Becton
Dickinson Immunocytometry Systems, San Jose, CA),
washed and mixed with magnetic beads coated with
sheep anti-murine IgG (Dynabeads, Dynal A.S., Norway),
at a ratio of 1 lymphocyte to 30 beads. Following a 30 min
incubation at 4°C with occasional gentle rotation, posi-
tive cells were removed by magnetic selection. The
depleted population contained <3% CD8+ cells as meas-
ured by flow cytometry.
CTL lines
Autologous αEN-EBV and allogeneic αJY CTL cell lines
were kindly provided by Dr. Edward Nelson, University of
California, Irvine. Both CTL lines were cultured in RPMI-
1640 (BioWhittaker) containing 10% FBS (Hyclone), 2Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/14
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mM L-glutamine, 100 U/ml penicillin, 100 µg/ml strepto-
mycin (Gibco) and supplemented with 10% conditioned
supernatant from MLR culture and grown at 37°C, 12%
CO2. To maintain cytotoxic activity, αJY and αEN-EBV
CTL were re-stimulated with their respective stimulator
cells (irradiated with 10000 rad) every 7 days and
expanded by feeding cells with conditioned media at 3
days after re-stimulation.
Flow cytometric analysis
Immunophenotypic analysis of CTL cultures was per-
formed by flow cytometry. Cells were resuspended in
Blocking Buffer consisting of DPBS (BioWhittaker, Walk-
ersville, MD), 5% Human Serum (Gemini, Calabasas, CA)
and 0.1% Sodium Azide (Sigma, St Louis MO) and placed
at 4°C for 30 min. The cells were then centrifuged (1000
RPM, 5 min) and resuspended at 1 × 106 cells/100 µl in
cold medium consisting of DPBS, 2%BSA (Sigma) and
0.1% Sodium Azide (Sigma). Cell suspensions were run
against the following simultest antibody panel: CD45/
CD14, CD3/CD4, CD3/CD8, CD3/CD19, and CD3/
CD16,56 (Becton-Dickinson, San Jose CA). The γ1/γ2a
simultest served as the negative control (Becton-Dickin-
son). Cells were stained for 30 min at 4°C, washed once
and then fixed with 300 µl per tube of fresh 1% parafor-
maldehyde (Sigma) in DPBS. Cell phenotype was then
analyzed using a FACScan instrument (Becton-Dickinson
Immunocytometry Systems, San Jose, CA) equipped with
a 15 mW argon-ion laser.
Chromium release assay
Cytotoxicity of CTL was assessed using the standard
51Chromium-release assay. Briefly, one million target cells
were labeled at 37°C for 1 h with 100 µCi Na2
51CrO4
(New England Nuclear, Boston, Ma). Target cells were
washed and resuspended in CM at 5 × 104 cells/ml. Five
thousand target cells per well (100 µl) were added to a 96
well plate (Costar, Cambridge, MA) following the appro-
priate number of effector cells (100 µl/well). The defined
effector:target (E:T) ratios were plated in triplicate. Cyto-
toxicity assays were performed at 37°C for 4 h. After incu-
bation, cell-free supernatants were collected using a
Skatron harvester and analyzed in a gamma counter (LKB-
Wallac CliniGamma 1272, Wallac, Finland). Percent spe-
cific lysis was calculated using the following equation:
(ER - SR)/(MR - SR) × 100, where ER = experimental
release, SR = spontaneous release and MR = maximum
release.
Granzyme B ELISPOT assay
To measure GrB secretion, MultiScreen-IP plates (PVDF
membrane, Millipore, Bedford MA) were coated over-
night at 4°C with 100 µl/well of anti-human GrB capture
antibody (clone GB-10, PeliCluster, Cell Sciences, Nor-
wood MA) diluted to 7.5 µg/ml in PBS. After overnight
incubation, coated plates were washed 4 times with PBS
and blocked with 200 µl/well of assay medium consisting
of RPMI-1640 (BioWhittaler), 10% FBS (Hyclone), 2 mM
L-glutamine, 20 mM HEPES, 0.1 mM NEAA, 1 mM
Granzyme B (GrB) secretion by αEN-EBV CTL cell line in  the ELISPOT assay Figure 1
Granzyme B (GrB) secretion by αEN-EBV CTL cell 
line in the ELISPOT assay. Effector cells (104, 5 × 103 or 
2.5 × 103 cells per well) were run against EN-EBV or K562 
(NK control) targets, 5 × 104 cells per well, in a 4 h assay at 
37°C. Data is presented as spots per well ± SD and is repre-
sentative of 3 experiments. Similar results obtained for αJY 
CTL.
α α α αEN-EBV only + EN-EBV targets + K562 targets
10K
5K
2.5K
49 ± 2.6 209 ± 9.0 84 ± 17.0
27 ± 2.5 145 ± 8.4 59 ± 11.0
13 ± 3.1 80 ± 9.5 18 ± 12.7
Cytotoxicity of αEN-EBV CTL in the 51Cr-release assay Figure 2
Cytotoxicity of αEN-EBV CTL in the 51Cr-release 
assay. The αEN-EBV CTL cell lines were utilized as effector 
cells. Various numbers αEN-EBV CTL cells were tested 
against 5 × 103 target cells for 4 h at 37°C. Data is represent-
ative of 3 experiments. Similar results obtained for αJY CTL.
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sodium pyruvate, 100 U/ml penicillin and 100 µg/ml
streptomycin (Gibco) for 2 h at 37°C, 5% CO2. Targets
(C1R.A2) were pulsed with 5 µg/ml FMP or 3 µM MART-
1 peptide for 2 h at 37°C prior to use in assay. Unpulsed
C1R.A2 and C1R.A2 pulsed with MART-1 peptide served
as controls. Effector cells (100 µl/well) were added to trip-
licate wells at specified concentrations followed by 5 × 104
target cells per well (100 µl). Negative controls consisted
of effector cells in the absence of target cells, target cells in
the absence of effector cells and media only.
After effector and target cells were incubated as specified,
the plates were washed 6 times with PBS + 0.05% Tween
20 and 100 µl/well of biotinylated anti-human GrB
detecting antibody (clone GB-11, PeliCluster, Cell Sci-
ences) diluted to 0.25 µg/ml in PBS + 1% BSA + 0.05%
Tween 20 was added. Plates were incubated with detecting
antibody for 3 h at room temperature, washed 4 times
with PBS and 50 µl of Streptavidin-Alkaline Phosphatase
(Gibco BRL Life Technologies) diluted 1:1500 in PBS +
1% BSA was added. After 1 h incubation at room temper-
ature, the plates were washed 4 times with PBS and the
spots visualized with 100 µl/well of filtered BCIP-NBT
phosphatase substrate (KPL, Gaithersburg, MD). Plates
were developed for 30 min at room temperature in the
dark and the reaction stopped by rinsing plates with dis-
tilled water. The membranes were air-dried and spots per
well were subjected to automated evaluation using the
ImmunoSpot Imaging Analyzer system (Cellular Technol-
ogy Ltd, Cleveland, OH).
IFN-γ ELISPOT assay
For assessing IFN-γ secretion, MultiScreen-IP plates (PVDF
membranes, Millipore) were coated overnight at room
temperature with 50 µ/well of anti-human IFN-γ capture
antibody (Biosource, International, Camarillo CA)
diluted at 20 µg/ml in PBS. After overnight incubation at
room temperature, coated plates were washed and
blocked as stated above. Effector cells (100 µl/well) were
added to triplicate wells at specified concentrations fol-
lowed by 5 × 104 target cells per well (100 µl). After effec-
tor and target cells were incubated at 37°C, the plates were
washed with PBS + 0.05% Tween 20 and 50 µl/well of
biotinylated anti-human IFN-γ detecting antibody
(PharMingen, San Jose, CA) diluted to 1.3 µg/ml in PBS
with 1% BSA and 0.05% Tween 20 was added. Plates were
incubated with detecting antibody for 2 h at room temper-
ature, washed 4 times with PBS and 50 µl of Streptavidin-
Alkaline Phosphatase (Gibco BRL Life Technologies)
diluted 1:1500 in PBS with 1% BSA was added. After 1 h
incubation at room temperature with Streptavidin-Alka-
line Phosphatase, the plates were washed and the spots
visualized and enumerated as stated above.
Statistical analysis
Statistical analysis was performed using Pearson correla-
tion coefficient (R2).
Results and Discussion
Granzyme B is a potential candidate molecule for measur-
ing tumor specific T-cell responses via the ELISPOT
method. This molecule is present in CTL and NK cells and
is constitutively expressed in memory but not naïve CTL
[15,19-24]. Upon effector-target interactions, GrB is rap-
idly released by cytolytic lymphocytes in a calcium
dependent manner and therefore may be used to assess
cell-mediated cytotoxicity. In this study we investigated
whether the GrB ELISPOT assay can reliably measure CTL
responses. The endpoint application of the assay is to
evaluate clinical samples from patients vaccinated with
various peptides.
Unlike the IFN-γ ELISPOT which is widely utilized, the
application of the GrB ELISPOT has been limited [17].
Our laboratory has optimized the GrB ELISPOT assay for
various cytolytic cells including αEN-EBV and αJY CTL cell
lines. The assay measured stimulated GrB secretion when
CTL were incubated with their specific targets (Fig. 1).
When NK targets were utilized, significantly less GrB
release was observed. Greater cytotoxic activity was meas-
ured in the 51Cr-release assay when αEN-EBV CTL were
tested against relevant compared to irrelevant targets (Fig.
Specificity of GrB and IFN-γ secretion by αFMP-CTL in the  ELISPOT assays Figure 3
Specificity of GrB and IFN-γ secretion by αFMP-CTL 
in the ELISPOT assays. Human αFMP-CTL (7 day culture, 
5 × 103 cells per well) were run alone (A) or against various 
target cells (5 × 104 cells per well): C1R.A2 (B), C1R.A2 
pulsed with 5 µg/ml FMP (C) or C1R.A2 pulsed with 3 µM 
MART-1 (D). Effector and target cells were incubated for 4 h 
at 37°C assays. Data is presented as spots per well ± SD and 
is representative of 3 experiments.
A
Granzyme B IFN-γ γ γ γ
B
C
D
44 ± 8.5
201 ± 11.1
4 ± 2.5 58 ± 7.2
2 ± 1.2
42 ± 8.3 3 ± 2.1
141 ± 15.9Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/14
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2). One reason for the low-level residual activity observed
in both assays is possible NK cell contamination in the
culture as the αEN-EBV CTL cell line is not a clone. These
data demonstrate that the GrB ELISPOT assay is capable of
measuring MHC restricted cytolytic activity. Non-stimu-
lated effector cells secreted low amounts of GrB indicating
that the ELISPOT assay mainly detected stimulated and
not spontaneous (constitutive) release of GrB (Fig. 1).
Beyond measuring functional activity, the ELISPOT assays
also quantify frequency of specific effector cells. We inves-
tigated if evaluating GrB secretion in the ELISPOT assay
can accurately assess the frequency of CTL. We addressed
this issue by performing serial dilutions of the CTL lines.
The various dilutions of αEN-EBV CTL were then run
against a constant number of specific and non-specific tar-
get cells in the GrB ELISPOT assay. A significant correla-
tion between the number of CTL plated and the number
of spots per well was observed (R2 = 0.9626), thereby sug-
gesting that the GrB ELISPOT assay can accurately enu-
merate the precursor frequency of GrB-secreting cells (Fig.
1). Similar results were observed with αJY CTL (data not
shown). Our findings are in excellent agreement with
those of a previous report that utilized GrB transfected
CHO cells and T-cell lines as effector cells [17].
Since the GrB ELISPOT assay can accurately measure the
specific secretion of GrB by CTL cell lines, we generated
αFMP-CTL as a more clinically relevant model system to
assess whether the GrB ELISPOT assay can reliably detect
Correlation of GrB and IFN-γ secretion in the ELISPOT assay with cytotoxicity in 51Cr-release assay Figure 4
Correlation of GrB and IFN-γ secretion in the ELISPOT assay with cytotoxicity in 51Cr-release assay. Human α-
FMP-CTL (7 day culture) were used as effector cells. Target cells were C1R.A2 pulsed with FMP, 5 × 103 cells per well. Incuba-
tion time was 4 h at 37°C for all three assays. At the 10:1 effector:target ratio the spots in the IFN-γ ELISPOT assay were too 
numerous to count. Background (CTL alone) was subtracted from the results. Data is representative of 3 experiments.
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effector cell responses to specific peptides. Significant GrB
secretion was observed when αFMP-CTL were tested
against FMP-pulsed C1R.A2 (specific target, Fig. 3). When
the GrB ELISPOT assays were performed with a constant
number of target cells but varying numbers of effectors, a
strong correlation between the number of effector cells
and spots per well was shown (R2 = 0.9426, Fig. 4). Opti-
mal concentration of effector cells ranged between 104
and 103 cells per well based on experiments using several
donors (data not shown). At these effector cell concentra-
tions, GrB production could be reliably detected and
enumerated.
Cell-mediated cytotoxicity has conventionally been meas-
ured using the standard 51Cr-release assay [25], which
assesses CTL and NK cell functions via lysis of radioiso-
tope-labeled target cells. This assay is considered to be the
gold standard to evaluate CTL lytic activity. Recently, the
IFN-γ ELISPOT assay has become a surrogate measure of
CTL responses. We compared the GrB ELISPOT assay to
the 51Cr-release and IFN-γ ELISPOT assays to evaluate its
ability to quantify CTL lytic responses (Fig. 4). Both ELIS-
POT assays were significantly more sensitive than the
51Cr-release assay. At effector:target ratios of 50:1–12:1,
specific lysis was measurable via the 51Cr-release assay,
but the spots per well in the ELISPOT assays were too
numerous to count accurately (data not shown). Signifi-
cant IFN-γ and GrB secretion was evident at E:T ratios as
low as 0.2:1 (5000 targets/well), therefore, the optimal
ratios for the ELISPOT assays are below the level of sensi-
tivity of the 51Cr-release assay. However, when the opti-
mal number of CTL are used in each individual assay, the
amount of GrB and IFN-γ secreting cells in the ELISPOT
assays and cytotoxicity in the 51Cr-release assay have
shown excellent cross-correlation (R2 = 0.95).
To study the specificity of GrB secretion by αFMP-CTL, we
tested CTL reactivity against FMP-pulsed C1R.A2 (specific
targets) as well as non-pulsed and MART-1 pulsed C1R.A2
cells (non-specific targets) in the GrB ELISPOT assay.
K562 were utilized as a control for NK actitivity (data not
shown). Granzyme B secretion was antigen specific as
only wells with CTL and FMP-pulsed CIR.A2 contained a
substantial number of spots (Fig. 3). To further confirm
that we were measuring CTL activity, we removed CD8+
cells from the cultures using anti-CD8 mAb and magnetic
beads. After depletion, the percentage of CD8+ cells in the
cultures was decreased from 24.8 ± 2.9% to 2.7 ± 0.4%.
Granzyme B and IFN-γ secretion was compared for both
total and CD8+ depleted CTL cultures (Fig. 5). Abrogation
of both GrB and IFN-γ secretion was observed when CD8+
cells were depleted from the CTL cultures. These results
confirm that at least in this system both factors are
secreted by CD8+ cells, however it is not clear if the same
effector cell releases GrB and IFN-γ.
The dynamics of GrB and IFN-γ secretion differ. Granzyme
B secretion was detectible as early as 10 min after initial
contact of effectors and targets in most experiments. Sig-
nificant amounts of GrB spots were observed within 30
min of incubation with maximal secretion at 4 h. Longer
incubation did not increase GrB secretion (not shown). In
contrast, measurable amounts of IFN-γ spots were
observed only after 1 h of incubation with significant IFN-
γ secretion measured at 4 h (Fig. 6).
The difference in the observed pattern of GrB and IFN-γ
secretion parallels the well-defined dynamics of CTL effec-
tor functions. When CTL or NK cells interact with target
cells, IFN-γ is secreted within hours whereas GrB is
released very rapidly (within minutes) from preformed
granules. Using effector cells with NK activity, we have
shown that treatment with Brefeldin A, a protein secretion
blocker, significantly decreases IFN-γ but not GrB produc-
tion. In contrast, BAPTA-AM, which sequesters intra-cellu-
lar calcium and therefore inhibits degranulation, only
abrogated GrB secretion (manuscript in preparation). The
fact that the number of effectors spontaneously secreting
GrB is somewhat higher than the number secreting IFN-γ
(Fig. 3), suggests that the GrB measured in the ELISPOT
could be present in preformed granules. However, the
Effector cells secreting GrB and IFN-γ in the ELISPOT assays Figure 5
Effector cells secreting GrB and IFN-γ in the ELIS-
POT assays. Human αFMP-CTL (7 day culture) or cultures 
depleted of CD8+ cells were used as effector cells (5 × 103 
cells per well). Target cells were C1R.A2 pulsed with FMP (5 
× 104 cells per well). CD8+ cells were removed from effec-
tor cell cultures using anti-CD8 mAb and magnetic beads. 
Effector and target cells were incubated for 4 h at 37°C. Data 
is presented as spots per 105 cells ± SD and is representative 
of 3 experiments.
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spontaneous release of GrB could also be due to the acti-
vation state of cytotoxic cells. The amount of GrB released
by effector cells alone was similar to the amount released
by cells stimulated with irrelevant targets. Granzyme B is
consistently expressed in activated cytolytic cells espe-
cially CD8+ CTL [19,23]. In activated CTL, cross-linking
of the TCR is sufficient to trigger the release of GrB from
preformed granules as well as the rapid synthesis of new
GrB.
Although all three assays correlated, there are numerous
advantages to utilizing the ELISPOT assays over the stand-
ard  51Cr-release assay. The ELISPOT assays use a lower
number of effector cells to accurately assess activity. The
high sensitivity and specificity of the ELISPOT assays are
beneficial for monitoring clinical trials where frequently
there are limited numbers of patients' cells available. The
ELISPOT assays also enumerate antigen specific lym-
phocyte frequency by measuring secretion of a specific
immune protein. As such, the ELISPOT assays are both
qualitative and quantitative. Additionally, the problems
associated with the labeling efficiency of targets are not a
concern with the ELISPOT assays. Recently, a Lysispot
assay and a flow cytometric assay were developed as alter-
natives to the 51Cr-release assay [26-28]. The Lysispot
assay utilizes β-galactosidase transfected cell lines as tar-
gets and was shown to measure direct lytic ability of T-cell
clones [26]. Although this assay can enumerate the
number of lytic CTL, it detected CTL activity in a similar
range as the 51Cr-release assay [26]. The flow cytometric
Time course of GrB and IFN-γ secretion in the ELISPOT assays and cytotoxicity in 51Cr-release assay Figure 6
Time course of GrB and IFN-γ secretion in the ELISPOT assays and cytotoxicity in 51Cr-release assay. Human 
αFMP-CTL (7 day culture) were used as effector cells (5 × 103 cells per well). Target cells were C1R.A2 pulsed with FMP (5 × 
104 cells per well). Effector and target cells were incubated for the specified times at 37°C. A table containing the number of 
spots per 105 cells is provided to better clarify the data. Background spots (CTL alone) were subtracted from the results. Data 
is an average from three experiments.
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based assays can assess target cell cytotoxicity as well as
identify the phenotype of the effector cells mediating the
immune response [27,28]. Much like the Lysispot assay,
the flow-based assays are not as sensitive and require a
greater number of effector cells compared to the ELISPOT
assay.
Both the GrB and IFN-γ ELISPOT assays are superior alter-
natives to the 51Cr-release assay to test CTL response.
However, when compared with the IFN-γ ELISPOT, the
GrB ELISPOT assay is more rapid and may be a more
direct measure of antigen specific CTL lytic activity. Pre-
liminary research with PBMC samples from cancer
patients suggests that the GrB ELISPOT assay may be suc-
cessfully applied to evaluate CTL precursor frequency.
With cancer patient samples, these preliminary results
obtained from the GrB and the standard 51Cr-release
assays tended to correlate, whereas correlation between
the GrB and IFN-γ ELISPOT assays was patient and treat-
ment dependent (data not shown). These findings are in
agreement with comparisons between the IFN-γ ELISPOT
and the Lysispot assay [26] and further confirm that cyto-
lytic function and cytokine production are probably regu-
lated independently at the molecular level.
The role of perforin in immuno-surveillance and rejection
of tumors has been well established but the role of GrB is
still controversial [29,30]. A recent study demonstrated
that GrB is not critical for CTL perforin-mediated rejection
of spontaneous or experimental tumors in mice [29].
These findings are in contrast to previous studies that have
suggested that GrB plays a critical role in controlling
tumors in vivo [31-35]. Regardless of the role of GrB in
cell-mediated killing, GrB expression is restricted to CTL
and NK cells and therefore the release of GrB is a more
specific measure of cytotoxic lymphocytes than IFN-γ
[15,20,21]. As such, simultaneous use of the IFN-γ and
GrB ELISPOT assays may provide important immunolog-
ical insight into patient responses to cancer vaccines that
may then be directly assessed against clinical outcome.
Conclusions
In our laboratory, the GrB ELISPOT assay was shown to
accurately measure stimulated GrB secretion by various
CTL effector cells. The precursor frequency of antigen-spe-
cific T-cells could be reliably enumerated via the GrB ELIS-
POT using log-fold lower effector cell numbers than
required for the 51Cr-release assay. The high sensitivity
and specificity of the GrB ELISPOT might prove beneficial
for monitoring clinical trials where there are limited num-
bers of patient cells available for immunological monitor-
ing. Detection and enumeration of low-frequency, tumor-
specific CTL and their specific effector functions and any
correlation with clinical responses will help to improve
cancer vaccine design in the future.
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